Cardeation Capital will invest in emerging healthcare technology companies working in the cardiovascular space. Its mission is to spur developments in diagnostics, treatments and care for heart disease and stroke and their risk factors, such as diabetes.
The three organizations each committed $10 million to the fund. Aphelion Capital, a healthcare and medical technology venture capital firm, will manage Cardeation Capital.
“We expect that Cardeation Capital, working closely with our world-renowned clinicians at UPMC Heart and Vascular Institute, will play a critical role in this strategy for the benefit of our patients,” C. Tal Heppenstall, executive vice president of UPMC and president of UPMC Enterprises, said in a May 17 statement.
More articles on health IT:
Epic adds patient intake tools to App Orchard
Cleveland Clinic to open 21k-square-foot biobank
HIMSS unveils resource to help hospitals navigate interoperability tools
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.